Stockscreener 앱 받기
0.747
6.11%
0.043
시장 영업 전:
.75
0.003
+0.40%
전일 마감가:
$0.704
열려 있는:
$0.795
하루 거래량:
99,548
Relative Volume:
2.37
시가총액:
$32.15M
수익:
-
순이익/손실:
$-13.25M
주가수익비율:
-2.1144
EPS:
-0.3533
순현금흐름:
$-8.02M
1주 성능:
-4.12%
1개월 성능:
-23.97%
6개월 성능:
-43.41%
1년 성능:
-12.12%
1일 변동 폭
$0.7145
$0.80
1주일 범위
$0.6781
$0.80
52주 변동 폭
$0.6781
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.747 | 33.34M | 0 | -13.25M | -8.02M | -0.3533 |
VRTX
Vertex Pharmaceuticals Inc
|
484.83 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
768.58 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
867.94 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.30 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
327.53 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Balance Sheet - TradingKey
Estrella Immunopharma Inc (ESLA) Cash Flow - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.750|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.780| - TradingKey
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella doses first patient in EB103 trial expansion phase - Investing.com
Estrella doses first patient in EB103 trial expansion phase By Investing.com - Investing.com Canada
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history - Yahoo Finance UK
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low VolatilityCalendar Spread Trade - dars.gov.et
Investigation launched into Estrella Immunophar... - Pluang
AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders - GlobeNewswire Inc.
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. ... - Caledonian Record
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ESLA Q2 2026 Earnings: Wider-than-Expected Loss Triggers Stock DeclineEarnings Cycle Report - dars.gov.et
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026 - Minichart
Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to earnings forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Estrella Immunopharma Warrants (ESLAW) Edge Lower Amid Thin TradingRisk Parity Rebalance - dars.gov.et
Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Estrella Immunopharma, Inc.(NasdaqCM: ESLA) added to Russell 3000E Value Benchmark - marketscreener.com
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Wider-than-Expected Loss Drives Stock Volatility - dars.gov.et
Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA) - TradingView
ESLA Q1 2026 Earnings: EPS Misses Estimates by 90.6% Amid Pre-Revenue PhaseSlow Growth Warning - dars.gov.et
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc - TradingKey
Estrella Immunopharma Inc (ESLAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Estrella Immunopharma Inc 주식 (ESLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xu Jiandong | Chief Financial Officer |
Sep 22 '25 |
Buy |
1.16 |
1,000 |
1,160 |
16,700 |
| Xu Jiandong | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.04 |
100 |
104 |
264,588 |
0.91%
0.66%
자본화:
|
볼륨(24시간):